Publications by authors named "D Schoenfeld"
The cytokine interleukin-18 (IL-18) has immunostimulatory effects but is negatively regulated by a secreted binding protein, IL-18BP, that limits IL-18's anti-cancer efficacy. A "decoy-resistant" form of IL-18 (DR-18), that avoids sequestration by IL-18BP while maintaining its immunostimulatory potential, has recently been developed. Here, we investigated the therapeutic potential of DR-18 in renal cell carcinoma (RCC).
View Article and Find Full Text PDFArticle Synopsis
- A study looked at how quickly treating strokes improves patient recovery, especially in the first six hours after a stroke happens.
- By reviewing different research studies, they found that saving time before starting treatment leads to better outcomes for patients.
- For every hour saved before treatment begins, patients had a 22-25% higher chance of doing better after 90 days.
Purpose: Immune checkpoint inhibitors have revolutionized the treatment of renal cell carcinoma (RCC), but many patients do not respond to therapy and the majority develop resistant disease over time. Thus, there is increasing need for alternative immunomodulating agents. The co-inhibitory molecule T-cell immunoglobulin and ITIM domain (TIGIT) may play a role in resistance to approved immune checkpoint inhibitors and is being investigated as a potential therapeutic target.
View Article and Find Full Text PDFGP100 expression is variable in intensity in melanoma.
Cancer Immunol Immunother
August 2024
Drugs or cellular products that bind to gp100 are being investigated for treatment of cutaneous melanoma. The relative specificity of gp100 expression in melanocytes makes it an attractive target to harness for therapeutic intent. For example, Tebentafusp, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, has generated significant enthusiasm in recent years due to its success in improving outcomes for uveal melanoma and is being studied in cutaneous melanoma.
View Article and Find Full Text PDF